Payment & Shipping Terms:
|Product Name:||Artemether Injection||Composition:||Each 1mL Ampule Contains:40MG 80MG Artemether.|
|Indications:||Antimalarial Drug. It Is Indicated For The Treatment Of All Kinds Of Malarias, Including The Chloroquine-resistant Malaria And The First Aid Of Fata Malaria.||Storage Instructions:||Store In A Cool, Dry, Dark Place.|
|Expiration Date:||3 Years|
anti malaria tablet,
Artemether Injection 40MG / ML 80MG / ML Anti Malaria 6AMPULES / BOX
ARTEMETHER INJECTION 40MG 80MG/1ML
Each 1mL ampule contains:40MG 80MG Artemether.
Artemether is synthetised from Artemisinin using methanol and a catalyst in hydrochloric acid medium. This
results in the production of predominantly βα-artemether. The alpha-epimer is also present and causes a difficult purification of the product.Both the alpha and the βα-epimers are active antimalarials.
It is the purification and separation of alpha from βαthat leads to low yields and hence this increases the cost
price of Artemether significantly.
Artemether has major antimalarial properties. Chloroq-uine-resistant or multi-resistant strains of P.falciparum have a great susceptibility to Artemether. The schizont-icidal activity of Artemther is due to the destruction of the asexual erythrocytic forms of P.falciparum and P.
vivax. Artemether is effective against all strains resistant to the other antimalarial agents. No cross-resistance is detected with chloroquine.
Pharmacokinetic data in humans are sparse, with no data demonstrating the rate or extent of absorption or
the systemic distribution of artesunate. After parenteral administration, artesunate is rapidly hydrolyzed to the
active metabolite dihydroartemisinin. The oral formulation is probably hydrolysed completely before entering
the systemic circulation. Peak serum levels occur within one hour of an oral dose of artesunate and persist for
up to 4 hours. Following intravenous administration, elimination half-life of 45 minutes has been reported. Dihydroartemisinin has a plasma elimination half-life of less than 2 hours, which may slow the development of resistance to artesunate.
Antimalarial drug. It is indicated for the treatment of all kinds of malarias, including the chloroquine-resistant malaria and the first aid of fata malaria.
Artemether is contraindicated in patients with hypersensitivity to artemether or other artemisinin compounds.
Artemether is not recommended in the first trimester of pregnancy because of limited data.
DOSAGE AND DIRECTIONS FOR USE:
Intramuscular injection. Five days course with the dose of 480mg for adults: once (80mg) daily for five
consecutive days with the first dose doubled. For children, the first dose is 3.2mg/kg bodyweight, followed
with 1.6mg/kg bodyweight every time from the 2nd day to 5th day.
SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Artemether has been remarkably well-tolerated, and appears less toxic than quinine or chloroquine; adverse effects include bradycardia,
electrocardiogram abnormalities, gastrointestinal disturbances (nausea, abdominal pain, diarrhoea - oral
therapy only), dizziness, injection site pain, skin reactions, and fever. Transient decreases in neutrophils and
reticulocytes have been reported in some patients treated with artemether.
Drug induced fever has been observed with artemether. Mild reactions were seen in patients to whom
artemether had been administered intramuscularly. These included nausea, hypotension, dizziness and tinnitus.
These side effects were also reported: dark urine, sweating, somnolence, and jaundice. There were no deaths
or any other side effects. No irreversible side effects were seen.
Slight rise of SGOT and SGPT may occur in individual cases. Neurological side effects have not yet been
observed in clinical use but clinical trials suggest that coma may be prolonged in patients treated with artemether and there was an increased incidence of convulsions in one trial in cerebral malaria. Transient first degree
heart block has been documented in three patients receiving artemether.
Neurotoxicity has been observed in animal studies but not in humans.
Cardiotoxicity has been observed following administration of high doses of Artemether.
Studies and reviews in the literature demonstrated that the active substance of Artemether had no interactions with other drugs on decreasing therapeutic effects and increasing toxicity and side effects in human bodies.
Although no case of overdosage has been documented, in case of accident, symptomatic treatment is
recommended under the instruction of doctors.
Preserve in well closed container,protected from light and stored in a cool place.